ZKB/CALL/ELI LILLY & CO/900/0.01/27.09.24 Share Price

Warrant

LLYAIZ

CH1305143419

Real-time Bid/Ask 07:32:19 23/05/2024 pm IST
0.27 CHF / 0.28 CHF +1.85% Intraday chart for ZKB/CALL/ELI LILLY & CO/900/0.01/27.09.24
Current month+17.39%
1 month+35.00%
Date Price Change
21/24/21 0.27 +35.00%
16/24/16 0.2 -4.76%
15/24/15 0.21 +31.25%

Delayed Quote Swiss Exchange

Last update May 21, 2024 at 08:50 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer ZKB
LLYAIZ
ISINCH1305143419
Date issued 08/03/2024
Strike 900 $
Maturity 27/09/2024 (127 Days)
Parity 100 : 1
Emission price 0.46 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 0.37 CHF
Lowest since issue 0.14 CHF
Delta0.34x
Omega 8.725
Premium15.98x
Gearing25.71x
Moneyness 0.8921
Difference Strike 92.81 $
Difference Strike %+10.31%
Spread 0.01 CHF
Spread %3.45%
Theoretical value 0.2750
Implied Volatility 30.92 %
Total Loss Probability 72.49 %
Intrinsic value 0.000000
Present value 0.2750
Break even 930.06 CHF
Theta-0.02x
Vega0.02x
Rho0.01x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9 USD
Average target price
850.4 USD
Spread / Average Target
+5.92%
Consensus
  1. Stock Market
  2. Warrants
  3. LLYAIZ Warrant